BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations

Core Insights - BioLife Solutions reported a preliminary fourth quarter revenue of $24.8 million, marking a 20% increase from $20.7 million in the same quarter of the previous year [1][7] - For the full year 2025, the company achieved revenue of $96.2 million, which is a 29% increase from $74.6 million in 2024, exceeding the previously raised guidance range [1][7] Financial Performance - The fourth quarter revenue growth was primarily driven by the biopreservation product line [2] - The company’s revenue from continuing operations for 2025 surpassed the high end of the guidance range of $95.0 million to $96.0 million, adjusted for the divestiture of the evo business [7] Strategic Positioning - Following the divestiture of the evo product line, BioLife is positioned as a pure-play cell processing company, focusing on high-value, recurring revenue franchises [2] - The company anticipates revenue growth across its product portfolio in 2026, along with an expansion of adjusted EBITDA margin due to increased operating leverage [3]